Cardiac-Derived Cell Therapy Shows Efficacy in Duchenne Muscular Dystrophy
CAP-1002 met primary and secondary end points in the HOPE-2 trial.
Capricor Therapeutics has announced positive data from the phase 2 HOPE-2 study (NCT03406780) of CAP-1002, their cardiac-derived cell therapy being investigated for the treatment of Duchenne muscular dystrophy (DMD).1
The randomized, double-blind, placebo-controlled, HOPE-2 trial met its primary end point, with decline on Mid-level Performance of Upper Limb (PUL) v1.2 slowed by 71% (P = .01) compared with placebo. The trial also met additional end points, with significant differences seen on the Full PUL v2.0 (P = .04) and Cardiac Endpoint of Ejection Fraction (P = .002) compared with placebo. These data were presented at the World Muscle Society Virtual Congress, September 20-24, 2021.
“This groundbreaking study is extremely exciting as we saw statistically significant changes of CAP-1002 in both skeletal and cardiac function. For these older boys who have limited therapeutic options, these data support the belief that CAP-1002 may become an important therapeutic option and possibly slow the progression of DMD,” principal investigator Craig McDonald, MD, professor and chair, Department of Physical Medicine and Rehabilitation, UC Davis, said in a statement.1
CAP-1002 is an allogeneic “off-the-shelf” cell therapy consisting of cardiosphere-derived cells. It was previously granted orphan drug designation by the FDA. Its immunomodulatory properties as well as its ability to regenerate skeletal and cardiac muscle cells have previously been demonstrated in preclinical studies.
READ MORE: SGT-001 Shows Efficacy in DMD in 1.5-Year Data
HOPE-2 enrolled 20 participants (12 placebo and 8 treated) with DMD across 9 sites in the US. These participants were on a stable regimen of steroids and around 80% were non-ambulant, with other demographic and baseline characteristics similar between the 2 groups. Participants were treated via intravenous delivery with either 150 million cells of CAP-1002 or placebo every 3 months, for a total of 4 doses over 1 year.
“The significance of this data is vitally important to patients and the DMD community. The data suggests that CAP-1002 slowed the decline of DMD in patients for whom few options currently exist,” Linda Marbán, PhD, chief executive officer, Capricor, added.1 “Now that we have clarity from the FDA and based on the strength of this data set, we are poised to embark on the HOPE-3 pivotal trial once we have secured an appropriate partner that can help drive CAP-1002 forward towards commercialization. Most importantly, we are thankful to the patients and families who participated in this study so that we can demonstrate the impact of CAP-1002 in treating DMD.”
Besides 2 hypersensitivity reactions seen early in the trial—which were mitigated with a common pre-medication regimen—CAP-1002 was well tolerated with no serious safety signals.
CAP-1002 was previously evaluated in the HOPE-Duchenne phase 1/2 trial (NCT02485938) for DMD-associated cardiomyopathy, which enrolled 25 participants across 3 sites in the US. Data from HOPE-Duchenne also demonstrated significant improvements in the mid-distal PUL in 8 of 9 patients treated with CAP-1002 compared with none of the patients treated with placebo.
CAP-1002 is now being developed collaboratively with Lonza, as Capricor announced in January 2021.2 The collaboration aims to expand Capricor’s manufacturing capacity for future clinical trials and potential commercialization.
“Capricor’s lead candidate CAP-1002 is demonstrating efficacy in late-stage clinical studies to significantly benefit patients,” said Alberto Santagostino, senior vice president and head, Cell and Gene Technologies, Lonza, in a statement at that time.2 “We will leverage our process development expertise and industrial manufacturing capabilities to enable Capricor to scale this therapy and make it available to patients globally, once approved for commercialization.”
